MINERALYS THERAPEUTICS, INC. Accretion (Amortization) of Discounts and Premiums, Investments
MINERALYS THERAPEUTICS, INC. (MLYS) reported Accretion (Amortization) of Discounts and Premiums, Investments of $9.27 million for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-11.
Financial Statements › Cash Flow › Operating Activities
us-gaap:AccretionAmortizationOfDiscountsAndPremiumsInvestments · last filed 2026-08-11
- MINERALYS THERAPEUTICS, INC. accretion (amortization) of discounts and premiums, investments for the quarter ending 2026-06-30 was $4.64M, a 108.30% increase year-over-year.
- MINERALYS THERAPEUTICS, INC. accretion (amortization) of discounts and premiums, investments for the quarter ending 2026-03-31 was $4.63M, a 342.16% increase year-over-year.
- MINERALYS THERAPEUTICS, INC. accretion (amortization) of discounts and premiums, investments for the quarter ending 2025-12-31 was $4.21M, a 214.73% increase year-over-year.
- MINERALYS THERAPEUTICS, INC. accretion (amortization) of discounts and premiums, investments for the quarter ending 2025-09-30 was $2.40M, a 11.65% decline year-over-year.
- MINERALYS THERAPEUTICS, INC. accretion (amortization) of discounts and premiums, investments for fiscal 2025 was $9.88M, a 5.04% increase from fiscal 2024.
- MINERALYS THERAPEUTICS, INC. accretion (amortization) of discounts and premiums, investments for fiscal 2024 was $9.40M, a 37.00% increase from fiscal 2023.
- MINERALYS THERAPEUTICS, INC. accretion (amortization) of discounts and premiums, investments for fiscal 2023 was $6.87M, a 957.78% increase from fiscal 2022.
- MINERALYS THERAPEUTICS, INC. accretion (amortization) of discounts and premiums, investments for fiscal 2022 was $649.00K.
| Period end | Accretion (Amortization) of Discounts and Premiums, Investments 3 month | Accretion (Amortization) of Discounts and Premiums, Investments 6 month | Accretion (Amortization) of Discounts and Premiums, Investments 9 month | Accretion (Amortization) of Discounts and Premiums, Investments 12 month |
|---|---|---|---|---|
| 2026-06-30 | $4.64M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-11 | $9.27M 10-Q · filed 2026-08-11 | $13.48M derived: sum of 3 quarters · filed 2026-08-11 | $15.87M derived: sum of 4 quarters · filed 2026-08-11 |
| 2026-03-31 | $4.63M 10-Q · filed 2026-05-06 | $8.83M derived: sum of 2 quarters · filed 2026-05-06 | $11.23M derived: sum of 3 quarters · filed 2026-05-06 | $13.46M derived: sum of 4 quarters · filed 2026-08-11 |
| 2025-12-31 | $4.21M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-12 | $6.60M derived: sum of 2 quarters · filed 2026-03-12 | $8.83M derived: sum of 3 quarters · filed 2026-08-11 | $9.88M 10-K · filed 2026-03-12 |
| 2025-09-30 | $2.40M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-10 | $4.63M derived: sum of 2 quarters · filed 2026-08-11 | $5.67M 10-Q · filed 2025-11-10 | $7.01M derived: sum of 4 quarters · filed 2026-08-11 |
| 2025-06-30 | $2.23M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-11 | $3.27M 10-Q · filed 2026-08-11 | $4.61M derived: sum of 3 quarters · filed 2026-08-11 | $7.32M derived: sum of 4 quarters · filed 2026-08-11 |
| 2025-03-31 | $1.05M 10-Q · filed 2026-05-06 | $2.38M derived: sum of 2 quarters · filed 2026-05-06 | $5.09M derived: sum of 3 quarters · filed 2026-05-06 | $7.94M derived: sum of 4 quarters · filed 2026-05-06 |
| 2024-12-31 | $1.34M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-12 | $4.05M derived: sum of 2 quarters · filed 2026-03-12 | $6.90M derived: sum of 3 quarters · filed 2026-03-12 | $9.40M 10-K · filed 2026-03-12 |
| 2024-09-30 | $2.71M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-10 | $5.56M derived: sum of 2 quarters · filed 2025-11-10 | $8.07M 10-Q · filed 2025-11-10 | $10.13M derived: sum of 4 quarters · filed 2025-11-10 |
| 2024-06-30 | $2.85M derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-12 | $5.36M 10-Q · filed 2025-08-12 | $7.42M derived: sum of 3 quarters · filed 2025-08-12 | $9.38M derived: sum of 4 quarters · filed 2025-08-12 |
| 2024-03-31 | $2.51M 10-Q · filed 2025-05-12 | $4.58M derived: sum of 2 quarters · filed 2025-05-12 | $6.54M derived: sum of 3 quarters · filed 2025-05-12 | $8.52M derived: sum of 4 quarters · filed 2025-05-12 |
| 2023-12-31 | $2.07M derived: 10-K 12 month − 10-Q 9 month · filed 2025-02-12 | $4.03M derived: sum of 2 quarters · filed 2025-02-12 | $6.01M derived: sum of 3 quarters · filed 2025-02-12 | $6.87M 10-K · filed 2025-02-12 |
| 2023-09-30 | $1.96M derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-12 | $3.94M derived: sum of 2 quarters · filed 2024-11-12 | $4.80M 10-Q · filed 2024-11-12 | $5.21M derived: sum of 4 quarters · filed 2024-11-12 |
| 2023-06-30 | $1.98M derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-13 | $2.84M 10-Q · filed 2024-08-13 | $3.25M derived: sum of 3 quarters · filed 2024-08-13 | $3.49M derived: sum of 4 quarters · filed 2024-08-13 |
| 2023-03-31 | $855.00K 10-Q · filed 2024-05-09 | $1.26M derived: sum of 2 quarters · filed 2024-05-09 | $1.50M derived: sum of 3 quarters · filed 2024-05-09 | $1.50M derived: sum of 4 quarters · filed 2024-05-09 |
| 2022-12-31 | $410.00K derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-21 | $649.00K derived: sum of 2 quarters · filed 2024-03-21 | $649.00K derived: sum of 3 quarters · filed 2024-03-21 | $649.00K 10-K · filed 2024-03-21 |
| 2022-09-30 | $239.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-07 | $239.00K derived: sum of 2 quarters · filed 2023-11-07 | $239.00K 10-Q · filed 2023-11-07 | |
| 2022-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-07 | $0.00 10-Q · filed 2023-08-07 | ||
| 2022-03-31 | $0.00 10-Q · filed 2023-05-15 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Viridian Therapeutics, Inc.\DE (VRDN) | United States | $2.342B | -5.38 |
| Harmony Biosciences Holdings, Inc. (HRMY) | United States | $2.399B | 11.67 |
| Vera Therapeutics, Inc. (VERA) | United States | $2.402B | -7.67 |
| uniQure N.V. (QURE) | $2.416B | -4.93 | |
| SELLAS Life Sciences Group, Inc. (SLS) | United States | $2.420B | -91.87 |
| Nurix Therapeutics, Inc. (NRIX) | United States | $2.457B | -5.39 |
| Zai Lab Ltd (ZLAB) | $2.241B | -113.34 | |
| Aurinia Pharmaceuticals Inc. (AUPH) | $2.207B | 7.18 | |
| SUPERNUS PHARMACEUTICALS, INC. (SUPN) | United States | $2.517B | -24.63 |
| Immunome Inc. (IMNM) | United States | $2.538B | -9.45 |